Poly(ADP-ribose) binds to the splicing factor ASF/SF2 and regulates its phosphorylation by DNA topoisomerase I by Malanga, M et al.
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2008
Poly(ADP-ribose) binds to the splicing factor ASF/SF2 and
regulates its phosphorylation by DNA topoisomerase I
Malanga, M; Czubaty, A; Girstun, A; Staron, K; Althaus, F R
Malanga, M; Czubaty, A; Girstun, A; Staron, K; Althaus, F R (2008). Poly(ADP-ribose) binds to the splicing factor
ASF/SF2 and regulates its phosphorylation by DNA topoisomerase I. Journal of Biological Chemistry,
283(29):19991-19998.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Journal of Biological Chemistry 2008, 283(29):19991-19998.
Malanga, M; Czubaty, A; Girstun, A; Staron, K; Althaus, F R (2008). Poly(ADP-ribose) binds to the splicing factor
ASF/SF2 and regulates its phosphorylation by DNA topoisomerase I. Journal of Biological Chemistry,
283(29):19991-19998.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Journal of Biological Chemistry 2008, 283(29):19991-19998.
Poly(ADP-ribose) binds to the splicing factor ASF/SF2 and
regulates its phosphorylation by DNA topoisomerase I
Abstract
Human DNA topoisomerase I plays a dual role in transcription, by controlling DNA supercoiling and by
acting as a specific kinase for the SR-protein family of splicing factors. The two activities are mutually
exclusive, but the identity of the molecular switch is unknown. Here we identify poly(ADP-ribose) as a
physiological regulator of the two topoisomerase I functions. We found that, in the presence of both
DNA and the alternative splicing factor/splicing factor 2 (ASF/SF2, a prototypical SR-protein),
poly(ADP-ribose) affected topoisomerase I substrate selection and gradually shifted enzyme activity
from protein phosphorylation to DNA cleavage. A likely mechanistic explanation was offered by the
discovery that poly(ADP-ribose) forms a high affinity complex with ASF/SF2 thereby leaving
topoisomerase I available for directing its action onto DNA. We identified two functionally important
domains, RRM1 and RS, as specific poly(ADP-ribose) binding targets. Two independent lines of
evidence emphasize the potential biological relevance of our findings: (i) in HeLa nuclear extracts,
ASF/SF2, but not histone, phosphorylation was inhibited by poly(ADP-ribose); (ii) an in silico study
based on gene expression profiling data revealed an increased incidence of alternative splicing within a
subset of inflammatory response genes that are dysregulated in cells lacking a functional
poly(ADP-ribose) polymerase-1. We propose that poly(ADP-ribose) targeting of topoisomerase I and
ASF/SF2 functions may participate in the regulation of gene expression.
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     Human DNA topoisomerase I plays a dual 
role in transcription, by controlling DNA 
supercoiling and by acting as a specific kinase 
for the SR-protein family of splicing factors. 
The two activities are mutually exclusive, but 
the identity of the molecular switch is 
unknown. Here we identify poly(ADP-ribose) 
as a physiological regulator of the two 
topoisomerase I functions. We found that in 
the presence of both DNA and the alternative 
splicing factor/splicing factor 2 (ASF/SF2, a 
prototypical SR-protein),  poly(ADP-ribose) 
affected topoisomerase  I substrate selection 
and gradually shifted enzyme activity from 
protein phosphorylation to DNA cleavage. A 
likely mechanistic explanation was offered by 
the discovery that  poly(ADP-ribose) forms a 
high affinity complex with ASF/SF2 thereby 
leaving  topoisomerase I available  for 
directing its action onto DNA. We identified 
two functionally important domains, RRM1 
and RS, as specific poly(ADP-ribose) binding 
targets. Two independent lines of evidence 
emphasize the potential biological relevance of 
our findings: i) in HeLa nuclear extracts, 
ASF/SF2- but not histone- phosphorylation 
was inhibited by poly(ADP-ribose); ii) an in 
silico study based on gene expression profiling 
data revealed an increased incidence of 
alternative splicing within a subset of 
inflammatory response genes that are 
dysregulated in cells lacking a functional 
poly(ADP-ribose) polymerase-1. We propose 
that poly(ADP-ribose) targeting of 
topoisomerase I and ASF/SF2 functions may 
participate in the regulation of gene 
expression. 
      
     DNA topoisomerase I (topo I) is a 
constitutively expressed multifunctional enzyme  
that localizes at active transcription sites (1,2). 
Its best known function is to control the 
topological state of DNA by relieving torsional 
stress that is generated following DNA strand 
separation during transcription, replication, 
repair (3-5). The catalytic mechanism involves 
the formation of a DNA-topo I complex 
(cleavage complex) with the enzyme being 
covalently bound to the 3’-end of the cleaved 
DNA strand through a tyrosine-phosphate ester 
bond. Cleavage complexes are usually short-
lived; their stabilization by compounds of the 
camptothecin (CPT) family of anticancer drugs 
may cause DNA strand break accumulation and 
eventually lead to cell death. Human topo I can 
relax both negative and positive supercoils by 
controlled rotation of the DNA strand 
downstream of the cleavage site followed by 
break resealing and restoration of an intact DNA 
duplex.   
     In addition to relaxing supercoiled DNA, 
human topo I also plays a major role in pre-
mRNA splicing, being endowed with a protein 
kinase activity targeted at a group of splicing 
factors of the Serine-Arginine (SR) rich protein 
family (6). SR-proteins function both as 
components of the basal RNA splicing 
machinery and as regulators of alternative 
splicing (7,8). Moreover, SR-proteins are 
involved in the control of mRNA transport and 
stability (8,9) and contribute to the maintenance 
of genomic stability (10). SR-proteins are 
structurally characterized by having one or two  
domains that include a RNA Recognition Motif 
(RRM) at the N-terminus, and a Serine-Arginine 
rich C-terminal domain (RS domain) containing 
a variable number of  SR dipeptidic repeats. 
Phosphorylation at Serine residues in such 
sequences regulates SR-protein functions as well 
as their subnuclear localization (7-9,11,12). 
Besides topo I, other kinases are also involved in 
SR-protein phosphorylation; these include the 
SR-protein specific kinases 1 and 2 (SRPK1 and 
SRPK2) and the cell cycle-dependent dual 
specificity kinase Clk/Sty (13). Moreover, 
Akt/protein kinase B phosphorylation of SR-
protein family members appears to play a critical 
role in signal transduction pathways linking 
extracellular stimuli (hormones, mitogens) to 
changes in gene expression via regulation of 
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alternative splicing and mRNA translation 
(14,15).  
Topo I depletion results in the 
hypophosphorylation of SR-proteins and 
impaired exonic enhancer-dependent splicing 
(16). Likewise, inhibition of topo I-dependent 
SR-protein phosphorylation by indolocarbazole 
antitumor drugs has been shown to interfere with 
the spliceosome assembly pathway, leading to 
altered gene expression and eventually to cell 
death (17). 
Thus, human topo I may either bind DNA and 
catalyze its relaxation, or bind SR-proteins and 
ATP and play the role of a kinase. The two 
activities are mutually exclusive and they are 
most likely the functional expression of distinct 
conformational states (18). What regulates such 
structural  and functional transitions is unknown. 
Human topo I is a member of the poly(ADP-
ribose)-binding family of proteins (19). 
Poly(ADP-ribose) (PAR) is the product of a class 
of enzymes known as PAR polymerases 
(PARPs) (20). PARPs utilize NAD+ as a source 
of ADP-ribose units and catalyze the covalent 
modification of a number of proteins 
(heteromodification), including themselves 
(automodification), with an array of linear or 
branched ADP-ribose chains of variable lengths; 
these polymers are then degraded by a specific 
PAR glycohydrolase (PARG), thus making the 
reaction reversible (20,21). PARP-1 and PARP-
2, the best known members of the PARPs’ 
family, depend on DNA strand breaks for 
activity and are responsible for most PAR 
synthesized in the nucleus of eukaryotic cells 
both under physiological and DNA damage 
conditions (20,21). Protein targeting by PARP-
bound polymers via non-covalent, yet specific 
interactions, is emerging as an important 
regulatory mechanism for diverse biological 
functions, including transcription, DNA damage 
signaling and checkpoint activation, proteasomal 
histone degradation and mitotic spindle 
formation (22,23). Topo I bears three PAR-
binding sites localized in domains that are 
critical for the catalytic activity of the enzyme on 
DNA and for its regulation (24). In fact, PAR has 
a dual effect on topo I: it inhibits DNA cleavage 
(thus preventing initiation of new catalytic 
cycles), while it stimulates  the religation activity 
of the enzyme blocked in a ternary complex with 
nicked DNA and CPT (thus counteracting the 
poisoning effect of the drug) (24). 
In this study we addressed the question whether 
PAR could also affect topo I kinase activity 
and/or act as a molecular switch of distinct topo I 
functions. ASF/SF2, a prototype of the SR-
protein family, was used as a specific substrate 
for the topo I kinase activity. 
 
MATERIALS AND METHODS 
 
     Purified human topo I was obtained from 
TopoGen. This enzyme undergoes spontaneous 
conversion into a 70 kDa form lacking the N-
terminal domain (ΔN-topo I). Full length His-
tagged human topo I expressed in a baculovirus 
system was from Jena Bioscience (distributed by 
Alexis). Topo I homogeneity was >95%. GST-
SRPK1 was from Upstate. Highly purified 
recombinant PARP-1 and PARP-2 were 
purchased from Alexis. 
Protein-free, affinity purified [14C]-poly (ADP-
ribose) (PAR), [32P]-PAR and [32P]-5’-end 
labeled ds-oligonucleotide, used as a topo I 
substrate in DNA cleavage assays, were prepared 
as previously described (24). 
All experiments were repeated at least three 
times and confirmed with different preparations 
of topo I, SR-proteins, PAR.  
 
Recombinant proteins - Human topo I was 
expressed in Saccharomyces cerevisiae 
EKY3 strain and purified essentially as 
described by Kowalska-Loth et al (25). 
Briefly, the expression of topo I was induced 
with 2% galactose. After 4 hours, cells were 
harvested, washed once with SED buffer (1 
M sorbitol, 25 mM EDTA, pH 8.0, 50 mM 
dithiotreitol (DTT) and treated with 5 mg/ml 
zymolyase 100T (Seikagaku) for 30 min at 
30 °C. Spheroplasts were pelleted by 
centrifugation and extracted twice with YLS 
buffer (20 mM Tris, pH 7.5, 0.5 M KCl, 1 
mM EDTA, 1 mM DTT, 10% glycerol, 1 
mM PMSF). Yeast extracts were adjusted to 
buffer B conditions (0.35 M NaCl, 25 mM 
Tris-HCl pH 7.5, 3 mM MgCl2, 10 mM β-
mercaptoethanol, 10% glycerol, 1mM 
PMSF), loaded onto heparin-agarose column 
(Bio-Rad) and eluted by increasing salt 
concentration. Topo I containing fractions 
were pooled and loaded onto a Ni-NTA 
agarose column (Qiagen) for further 
purification. Finally, purified topo I was 
concentrated on Biomax-5K columns 
(Millipore).  
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His-tagged SF2 was expressed in E.coli TG1 
strain and purified as described by Rossi et al 
(6). 
GST-tagged SF2 and SF2 fragments (GST-
ASF/SF21-119, GST-ASF/SF2120-194, GST-
ASF/SF2195-248) were expressed in E.coli strain 
BL21(DE) (Novagen) and purified on 
glutathione-agarose (Sigma) as previously 
described (25). GST-ASF/SF2195-248 was 
subjected to further purification on heparine-
agarose column after dilution in  50mM Tris-HCl 
buffer, pH 8.0, containing, 10 mM β-
mercaptoethanol, 10% glycerol, 1 mM EDTA, 
1mM PMSF. Elution was carried out in the same 
buffer with increasing NaCl concentrations (0.1-
1 M). Purified polypeptides were concentrated 
on Biomax-5K columns (Millipore) and buffer 
was exchanged to 20 mM HEPES, pH 7.4, 50 
mM NaCl, 75 mM KCl, 1 mM EDTA, 0.05 % 
Triton X-100, 10 % glycerol, 1 mM DTT, 1 mM 
PMSF. 
 
Topo I activity assays - Topo I DNA cleavage 
activity was assayed using a [32P]-5’-end labelled 
ds-oligonucleotide containing a single topo I 
binding/cleavage site, as previously reported 
(24). Reaction mixtures (15 µl) were assembled 
on ice and contained 50 mM Tris-HCl, pH 8.0, 
0.1 mM EDTA, 1 mM DTT, 0.01% Triton X-
100, 20 µM CPT, 0.2 mg/ml BSA, 2% glycerol, 
human topo I (0.2-0.27 pmol). Reaction was 
started by addition of  [32P]-5'-end labeled ds-
oligonucleotide (0.02-0.04 pmol; 0.5-1.1x106 
dpm/pmol) and carried on for 10-20 min at 37 
°C. After termination by addition of concentrated 
Laemmli  buffer, cleavage complexes were 
separated by SDS-PAGE on 7.5% 
polyacrylamide gels and visualized by 
autoradiography. When present, affinity purified 
PAR or ASF/SF2 were added to the reaction 
mixture at the amounts indicated in the Figures. 
Topo I kinase activity was assayed in the same 
buffer as indicated above in the presence of 10 
mM MgCl2 and 1 μM γ-[32P]-ATP (0.3x106 
dpm/pmol), in a final volume of 15 μl. 0.2 pmol 
of yeast-expressed human recombinant topo I 
and 0.7-2.8 pmol of recombinant His-ASF/SF2 
were used in each assay. After incubation at 37 
°C for 20 min, reaction was stopped by adding 
concentrated Laemmli buffer; ASF/SF2 
phosphorylation was visualized by 
autoradiography, after electrophoretic separation 
on 10% polyacrylamide gels (SDS-PAGE). 
ASF/SF2 phosphorylation by SRPK1 was 
assayed under the same conditions using 0.05 
pmol of the recombinant kinase. 
 
Double DNA cleavage/protein   phosphorylation 
assay - Recombinant human topo I (0.2 pmol) 
and recombinant His-ASF/SF-2 (2.8 pmol) were 
incubated at 37 °C for 20 min, in 50 mM Tris-
HCl, pH 8.0, containing 0.1 mM EDTA, 1 mM 
DTT, 10 mM MgCl2, 0.01% Triton X-100, 20 
µM CPT, 0.2 mg/ml BSA, 2% glycerol, [32P]-5'-
end labeled ds-oligonucleotide (0.034 pmoles; 
0.5-1.1x106 dpm/pmol), γ-[32P]-ATP (1.5 
pmoles; 0.3x106 dpm/pmol). Reaction mixtures 
were assembled on ice and transferred into a pre-
warmed water-bath immediately after γ-[32P]-
ATP addition.  Reaction products were analyzed 
by SDS-PAGE onto 4-15% polyacrylamide 
gradient gels, followed by autoradiography. 
When present, affinity purified PAR was added 
to the reaction mixture at the amounts indicated 
in the Figures. 
 
PAR binding assay - The PAR binding assay was 
carried on essentially as described by Panzeter et 
al (26). Proteins were immobilized on 
nitrocellulose either by western blotting after 
electrophoretic separation on polyacrylamide 
gels, or by slot blotting. Duplicate samples were 
either gold/Coomassie blue stained for protein 
visualization or probed with  [32P]-PAR , washed 
with 10 mM Tris-HCl, 0.15 M NaCl, 0.05% 
(v/v) Tween-20, pH 7.4 (TBST) and analyzed by 
autoradiography. Where indicated, 0.5 M NaCl 
was added to the washing buffer (0.5 M NaCl-
TBST). 
 
Protein extracts - HeLa S3 cells were cultured in 
complete DMEM under standard culturing 
conditions and harvested at a subconfluent stage 
to be used for nuclear and cytoplamic protein 
extract preparations, as previously described 
(27). 
ASF/SF2 or histone phosphorylation by 
endogenous kinase(s) was assayed in the 
conditions described by Rossi et al (6) using 0.5 
μl of extract (1 μg protein), in the presence or 
absence of PAR. Phosphorylated proteins were 
analyzed by SDS-PAGE and autoradiography. 
 
Quantitative analyses - Autoradiographic bands 
were quantified by scanning densitometry using 
the GS-710 Bio-Rad densitometer and the image 
analysis software QuantityOne (Bio-Rad). Data 
are expressed as mean of at least 3 independent 
experiments +/- standard deviation (SD). 
 
Bioinformatics - Peer-reviewed literature was 
surveyed for comparative genome-wide studies 
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of the transcriptomes of parp-1 knockout 
mammalian cells and their wild type 
counterparts, both under physiologic conditions 
and after exposure to cytotoxic stimuli. Then, 
gene expression profiling data were matched 
against the Alternative Splicing Annotation 
Project (ASAP II) database (28). Only genes 
coding for at least one expressed alternatively 
spliced isoform were taken as positive and 
expressed as percent of total analyzed genes.  
 
RESULTS 
 
     Topo I protein kinase activity is inhibited by 
PAR. In a reconstituted system consisting of 
PAR, topo I and an oligonucleotide substrate, we 
first demonstrated that site-specific DNA 
cleavage by either yeast- or baculovirus-
expressed recombinant human topo I is inhibited 
by PAR in a dose-dependent manner (Fig. 1A), 
as previously reported by us for topo I purified 
from human placenta (24). This inhibition is 
accompanied by the formation of a PAR-topo I 
complex (24); degradation of PAR to monomeric 
ADP-ribose abolished the inhibition (Fig. 1C). In 
order to investigate whether PAR had any 
influence on topo I kinase activity, we performed 
an ASF/SF2 phosphorylation assay in the 
presence or absence of the polymer. Topo I 
kinase targets the C-terminal RS domain of 
ASF/SF2 (29). His-tagged ASF/SF2 expressed in 
bacteria and purified by metal ion affinity 
chromatography, was used in this study. The 
recombinant protein migrated as a doublet in 
SDS-polyacrylamide gels (Fig. 2C); the shorter 
form is generated by proteolysis at the C-
terminus of the protein, which does not affect the 
protein’s capacity to be phosphorylated by SR-
protein specific kinases (29). Recombinant 
ASF/SF2 was phosphorylated by both topo I and 
the SR-protein kinase SRPK1 (Fig. 2A,B). 
However, when PAR was present in the kinase 
assay reaction mixture, topo I-catalyzed 
ASF/SF2 phosphorylation was dramatically 
reduced (Fig. 2B,E); the extent of inhibition was 
dependent on  PAR concentration (Fig.2B,E). 
Thus, PAR appears to function as a negative 
regulator not only of the DNA cleavage (Fig. 
1A) but also of the protein phosphorylation 
activity of topo I (Fig. 2B,E). Neither PARP-1 
nor PARP-2 in their native state affected topo I-
catalyzed ASF/SF2 phosphorylation (Fig. 2D). 
Furthermore, the polymer at several fold higher 
concentrations than that inhibitory on topo I, had 
only modest consequences on ASF/SF2 
phosphorylation by SRPK1 (Fig. 2A,E), thus 
pointing at a topo I-specific PAR effect. 
Noteworthy, while both topo I and SRPK1 
phosphorylate serine residues in the RS-domain 
of ASF/SF2, the reaction catalyzed by topo I has 
different specificity and kinetics from that of 
SRPK1 (29,30), implying the involvement of 
distinct mechanisms. 
 
     PAR and ASF/SF2 reciprocally antagonize 
their topo I inhibitory action. ASF/SF2 is known 
to inhibit DNA relaxation by topo I by 
interfering with the DNA cleavage step of the 
catalytic cycle (25,31-33). In Fig. 1B inhibition 
of topo I activity was achieved at an approximate 
topo I:ASF/SF2 molar ratio of 1:10. 
As both PAR and ASF/SF2 are negative 
regulators of topo I catalyzed DNA cleavage 
(Fig. 1), and ASF/SF2 phosphorylation is 
inhibited by PAR as well (Fig. 2), would PAR 
and ASF/SF2 together cause a complete 
silencing of topo I functions? To address this 
question, we set up an in vitro assay that allows 
simultaneous detection of topo I-DNA cleavage 
complex and phosphorylated ASF/SF2. 
Surprisingly, we observed a full restoration of 
topo I-catalyzed DNA cleavage while the 
inhibitory effect of PAR on topo I-dependent 
ASF/SF2 phosphorylation persisted (Fig. 3A). 
Reversal of topo I activity on DNA in the 
presence of both PAR and ASF/SF2 was clearly 
dependent on PAR concentration (Fig. 3A, right 
panel)  and also occurred in the absence of ATP 
(Fig. 3B, left panel). It is noteworthy that 
cleavage complex formation by a N-terminally 
truncated form of topo I (∆N-topo I, 70 kDa), 
which maintained full proficiency to relax DNA 
but had dramatically reduced protein kinase 
activity, was also inhibited by either PAR or 
ASF/SF2 individually (Fig. 3B, right panel). This 
is in agreement with our previous identification 
of PAR binding sites outside of the N-terminal 
domain of topo I (24). Like full length topo I, 
cleavage complex formation by ∆N-topo I was 
also restored in the presence of both PAR and 
ASF/SF2 (Fig. 3B, right panel). 
 
     ASF/SF2 is a novel member of the PAR-
binding protein family. We next hypothesized 
that PAR could bind to ASF/SF2 and that the 
formation of a stable PAR-ASF/SF2 complex 
might prevent either of the two interaction 
partners from binding topo I; as a consequence, 
topo I would be able to express its DNA 
cleavage activity. PAR binding was assessed 
using recombinant ASF/SF2, either His-tagged 
or as a fusion protein with GST. To identify the 
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specific domain(s) potentially involved in 
polymer binding, we constructed ASF/SF2 
deletion mutants, each comprising only one of 
the ASF/SF2 functional domains 
(RRM1/RRM2/RS)  (Fig. 4A).  PAR binding 
assays revealed that ASF/SF2 does indeed bind 
PAR (Fig. 4C,D). We identified the RRM1 and 
RS domains as potential targets of such 
interaction, while the RRM2 domain did not  
appear to possess any PAR binding activity (Fig. 
4C,D). Identical results were obtained both when 
proteins were first separated by SDS-PAGE and 
then transferred onto nitrocellulose by western 
blotting (Fig. 4B,D) and when native proteins 
where immobilized on the membrane by slot-
blotting (Fig. 4C), before being probed with 
radioactive PAR. Importantly, ASF/SF2-PAR 
binding appeared to be considerably stronger 
than topo I-PAR interactions:   nearly 90% topo I 
binding to PAR was destroyed by 0.5M NaCl; in 
contrast, most ASF/SF2-PAR complexes resisted 
high salt treatment (Fig. 5A). 
Next, the inhibitory effect of ASF/SF2 on DNA 
cleavage by a constant amount of topo I was 
titrated against increasing concentrations of 
PAR. We found that restoration of topo I DNA 
cleavage activity was strictly dependent on the 
relative amounts of the two negative effectors 
(Fig. 5B): 10 pmol polymeric ADP-ribose were 
sufficient to fully remove inhibition caused by 
2.8 pmol ASF/SF2; at higher PAR 
concentrations however, cleavage complex 
formation decreased again, probably as a 
consequence of topo I targeting by PAR 
molecules that exceeded ASF/SF2 binding 
capacity.  
 
     ASF/SF2-, but not histone- phosphorylation 
by HeLa nuclear extracts is inhibited by PAR. Is 
PAR able to modulate ASF/SF2 phosphorylation 
in a complex protein environment such as a 
nuclear extract? Fig. 6A demonstrate that PAR 
inhibits ASF/SF2 phosphorylation activity in 
HeLa nuclear extracts  in a dose-dependent 
manner. Notably, preincubation with DNA and 
CPT, but not with CPT alone, strongly reduced  
ASF/SF2 phosphorylation (Fig. 6B). Such a 
treatment has been demonstrated to cause 
specific inhibition of topo I kinase activity in 
HeLa nuclear extracts as a consequence of  drug-
induced topo I trapping in an inactive cleavage 
complex (6). 
In addition, the inhibitory action of PAR 
appeared to be selectively targeted to ASF/SF2 
kinase(s); histone H1 and H2B phosphorylation 
was not inhibited by PAR over the same dose 
range (Fig. 6C). 
Phosphorylation of endogenous nuclear extract 
proteins also appeared to be unresponsive to 
PAR (Fig. 6A and C, upmost part of the gels). 
 
 
DISCUSSION 
 
Human DNA topoisomerase I plays an important 
role in the regulation of gene expression by 
controlling DNA supercoiling on one side, and 
pre-mRNA splicing, on the other. In fact, in 
addition to relaxing supercoiled DNA, topo I  
exhibits a kinase activity targeted at the Serine-
Arginine rich family of splicing factors (SR-
proteins). How these functions are regulated is 
still unknown. Significantly, pharmacological 
inhibition of either of the two enzyme activities 
alters gene expression and eventually leads to 
cell death (3-5,17). 
     Here we show that PAR is a fine regulator of 
topo I functions (cf. Fig. 7). Both PAR and the 
splicing factor ASF/SF2 bind topo I and inhibit 
topo I-catalyzed DNA cleavage (24,25,31-33). 
Likewise, in the absence of ATP, PAR and 
ASF/SF2 each caused a dose-dependent 
silencing of topo I activity on DNA (Fig. 1). 
However, when these negative effectors were 
present simultaneously, the outcome was 
different and entirely unexpected: PAR and 
ASF/SF2 neutralized each other’s inhibitory 
actions and allowed restoration of the enzyme’s 
DNA cleavage activity (Fig. 3B). Thus PAR 
enabled topo I to direct its activity onto DNA 
under conditions that would otherwise be 
strongly inhibitory. In a more complex setting, 
with DNA, ATP and ASF/SF2 being incubated 
simultaneously with topo I, we observed that the 
enzyme phosphotransferase activity was by far 
favoured over the DNA cleavage activity; under 
such conditions topo I appeared in fact to be a 
more efficient kinase than a topoisomerase (Fig. 
3A); this is in agreement with observations 
reported by others (31). In addition, we found 
that PAR is able to restore topo I activity on 
DNA while at the same time reducing (but not 
abolishing) topo I-dependent ASF/SF2 
phosphorylation; the extent at which distinct  
topo I functions are either reactivated or 
inhibited appeared to be dependent on the 
amount of PAR (Fig. 3A, right panel). A 
mechanistic explanation of such an effect is 
offered by the finding that ASF/SF2 is a novel 
PAR binding partner, with the RRM1 and RS 
domains as specific PAR interaction targets (Fig. 
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4). Conceivably the formation of a PAR-
ASF/SF2 high affinity complex leaves topo I 
available for directing its action on DNA. 
Indeed, PAR-ASF/SF2 titration experiments 
(Fig. 3 and 5B) as well as the finding that PAR 
binds to ASF/SF2 more tightly than to topo I 
(Fig. 5A), are consistent with such a model. 
The fact that SRPK1, another SR-protein specific 
kinase, is only partially sensitive to PAR (Fig. 2) 
further emphasizes the specificity of PAR effects 
on topo I activities. Thus, PAR appears to be the 
first known physiological modulator of topo I 
kinase activity. Moreover, we found that 
ASF/SF2- but not histone phosphorylation by 
HeLa nuclear extracts is inhibited by PAR (Fig. 
6), suggesting that PAR might play a role as a 
regulator of ASF/SF2 phosphorylation status in 
the nucleus as well. Noteworthy, endogenous 
topo I could be identified as the main ASF/SF2 
kinase in the extract: in fact, enzyme trapping in 
a ternary complex with CPT and cleaved DNA 
abolished most of the ASF/SF2 phosphorylating 
activity (Fig. 6B).   In future studies it will be of 
interest to determine whether other members of 
the SR-protein family, that are also 
phosphorylated by topo I (6), may become 
targets of a PAR-reliant  control mechanism. 
How might regulation of topo I functions 
by PAR affect biological processes?  We propose 
a model by which PAR, through modulation of 
topo I substrate selection (either DNA or 
ASF/SF2), may participate in the coordination of 
DNA transcription and RNA splicing. Indeed it 
is now well established that RNA splicing and 
transcription are spatially and functionally 
coupled (34,35). This integration ensures that 
pre-mRNA processing is efficient and accurate 
and at the same time may prevent formation of 
potentially lethal DNA-RNA hybrids involving 
template DNA and nascent mRNA precursors 
(10). By virtue of its dual activity, involving 
control of DNA topology on one side and 
phosphorylation of splicing factors on the other, 
topo I may take part in transcription-splicing 
coupling mechanisms (31). Besides, several lines 
of evidence support a likely functional link 
between topo I and PARP-1 in the regulation of 
gene expression. In fact, both topo I and PARP-1 
localize to active transcription sites (1,2,36,37); 
furthermore, the two enzymes may form a 
complex resulting in a several fold enhancement 
of topo I DNA relaxation activity and/or loss of 
interaction with other protein partners (37-39). 
Additionally, ASF/SF2, topo I and PARP-1 share 
a high affinity for the phosphorylated carboxy-
terminal domain of RNA polymerase II and can 
be associated with the elongating polymerase in 
vivo (40). In the light of such evidences, we 
propose that topo I targeting by PAR may play a 
role during transcription elongation, when topo I 
activity is required both to relieve torsional stress 
generated by RNA polymerase II translocation 
along the DNA template (41), and to 
phosphorylate ASF/SF2 engaged in co-
transcriptional splicing events (16,17). The nick 
introduced onto the DNA template by topo I 
itself might constitute the activating signal for 
PARP-1, in analogy with the mechanism 
underlying PARP-1 and DNA topoisomerase II β 
cooperation at the level of transcription initiation 
(42). Alternatively, PAR synthesis might be 
stimulated by PARP-1 binding to altered DNA 
structures (43) that are formed during 
transcription. Newly synthesised PAR might 
then exert its regulatory role at two levels: 1) by 
attenuating (but not abolishing) topo I kinase 
activity that would be otherwise greatly favoured 
by the high local concentration of ASF/SF2, and 
2) by neutralizing the strong ASF/SF2 inhibitory 
effect on topo I-catalyzed DNA relaxation. Thus, 
an interplay between the levels of PAR and 
ASF/SF2 at transcription sites may control topo I 
activities and adds a further layer of regulation of 
gene expression. 
Significantly, the amounts of PAR  required to 
regulate topo I and induce the enzyme’s 
functional switch in vitro (5-20 pmol, i.e. 0.3-1.3 
μM, calculated as ADP-ribose moieties), are 
compatible with PAR cellular levels (0.11-1.3 
μM under physiologic conditions - up to 35 μM 
following DNA damage)  (44 and references 
therein,45) 
Lastly, several lines of evidence hint at a likely 
more direct involvement of the poly(ADP-
ribosyl)ation system in pre-mRNA processing: i) 
PAR binds to components of the RNA splicing 
machinery, i.e. the splicing factor ASF/SF2 (this 
study, Fig. 4) and several hnRNPs (46); ii) both 
PARP and PARG activities have been found in 
cytoplasmic ribonucleoprotein particles (47,48); 
iii) PARP-1 has been shown to possess RNA-
binding ability (49). The observation that 
ASF/SF2 phosphorylation – but not histone 
phosphorylation - in HeLa nuclear extracts is 
sensitive to PAR (Fig. 6) is also consistent with 
such a scenario. Moreover, the ASF/SF2 
domains targeted by PAR, i.e. the RRM1 and RS 
domains, are crucial for splicing functions, 
suggesting that PAR effects may extend beyond 
regulation of ASF/SF2 phosphorylation. 
Notably, the RS domain, which is present in 
several splicing factors, when tethered to a pre-
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mRNA is sufficient alone to promote pre-
spliceosome assembly and to support splicing 
(50). A speculation along this line is also 
supported by our results of an in silico study on 
published expression profiling data from wild 
type and parp-1 knockout cells and animal 
tissues (51-55). We found that within a group of 
genes involved in the response to cytotoxic 
stimuli, the incidence of alternative splicing 
increases specifically in the subset of parp-1 
dependent genes (Tab. I). The fraction of 
alternatively spliced genes in this subset was 
67.7-72.2% compared to 53-59% in the group of 
stress-regulated genes as a whole. Noteworthy, 
of the 18 genes that were reported to be 
differentially involved in the TNF-α response 
(54), 10 were not responsive either in wild type 
or knockout cells (possibly because of altered 
signaling), while  8  genes changed their 
expression levels in both cell types, but at 
different extents; the incidence of alternative 
splicing in this subgroup of genes was found to 
be 87.5% and reached 100% when considering 
only those genes (5 out of 8) that were expressed 
at lower levels in cells lacking a functional parp-
1; moreover, all these genes contained ASF/SF2 
binding sites  (data not shown). It should be 
emphasized that the number of published data 
that could be included in this study does not 
allow any conclusive statement yet. 
Nevertheless, our observations suggest a possible 
link between PAR/PARP-1 and alternative 
splicing  which warrants further validation and 
investigations.  
In conclusion, PAR may function as a molecular 
switch of topo I DNA cleavage/SR-protein 
kinase activities. We speculate that PAR 
targeting of topo I and/or SR-protein functions 
may play a role as a novel regulatory mechanism 
of gene expression. Such a mechanism might  
involve a specific set of genes and entail  
regulation of topo I-dependent phosphorylation 
of SR-proteins and/or modulation of SR-
proteins’ interaction with splicing 
coactivators/corepressors. Important clues may 
come from the identification of target genes, an 
achievement that should be greatly accelerated as 
more differential expression profiling data 
become available.  
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FIGURE LEGENDS 
 
Fig. 1. Both PAR and ASF/SF2 independently inhibit DNA cleavage by human recombinant topo I. 
Human recombinant topo I expressed either in yeast or, as a His-tagged protein, in a baculovirus 
system was incubated with a 5’-[32-P]ds-oligonucleotide containing a single topo I cleavage site in the 
absence or presence of either affinity purified PAR (A and C) or ASF/SF2 (B), as described under 
Materials and Methods. Panel C shows restoration of topo I DNA cleavage activity after PAR 
enzymatic digestion by PAR glycohydrolase (PARG). Topo I-DNA cleavage complexes were 
visualized by autoradiography following SDS-PAGE.  
 
Fig. 2. PAR inhibits ASF/SF2 phosphorylation. ASF/SF2 phosphorylation by either SRPK1 (0.05 
pmol; A) or topo I (0.2 pmol; B) was assayed in the absence or presence of increasing amounts of 
PAR; alternatively, 0.18 pmol of native PARP-1 or 0.3 pmol of PARP-2 were added together with 
topo I and ASF/SF2 into the kinase assay mixture (D).  Phosphorylated ASF/SF2 was visualized by 
autoradiography following SDS-PAGE (A,B,D). Duplicate gels were stained with Coomassie Blue for 
protein visualization (C). Autoradiographic bands were quantified by scanning densitometry and data 
were expressed  as percent of enzyme activity in the absence of PAR (E);  data from at least 3 
independent experiments (mean ± SD) are shown. 
M: molecular mass markers; size of protein markers (kDa) are indicated by numbers on the left in 
panel C 
 
Fig. 3. PAR removes ASF/SF2 inhibition on topo I DNA cleavage activity while modulating topo I 
protein phosphotransferase activity. Double DNA cleavage and ASF/SF2 phosphorylation assays (A) 
were performed as described in Materials and Methods, in the presence of both [32P]-ds-
oligonucleotide and [γ-32P]-ATP: simultaneous detection of cleavage complexes and phosphorylated 
ASF/SF2 was achieved by autoradiography following electrophoretic separation on polyacrylamide 
gradient gel (left). In similar assays, the effects of fixed amounts of ASF/SF2 (2.8 pmol) on topo I 
activities were titrated against increasing amounts of PAR and quantified by densitometric scanning of 
autoradiographic bands. Data are expressed as percent of topo I activity in the absence of PAR (line 
graph on the right: mean ± SD of at least three independent experiments).  
In the absence of ATP (B), DNA cleavage by either full length recombinant human topo I (gel on the 
left) or N-terminally truncated topo I (∆N-topo I) from human placenta (gel on the right), was carried 
on under the conditions described in the legends to Fig. 1. Full length topo I-DNA complex (faint band 
in the first lane of the gel on the right) was loaded on this gel as a marker (M) to allow for a direct 
comparison with the migration of  ∆N-topo I-DNA complex. 
*P-ASF/SF2: phosphorylated ASF/SF2. 
 
Fig. 4. ASF/SF2 is a PAR binding protein. Bacterially expressed recombinant ASF/SF2 or protein 
domains (A) were immobilized onto nitrocellulose by either western- (B,D) or slot-blotting (C). 
Duplicate samples were either stained for protein visualization or incubated with [32P]-PAR and 
autoradiographed for PAR-protein complex determinations. 1.5 μg of each protein was loaded on 
SDS-polyacrylamide gels; the amounts of slot-blotted native proteins ranged from 2.5 pmol 
(recombinant proteins 2-5) to 10 pmol (GST); the amounts of His-ASF/SF2 (1) used in the slot blot 
PAR binding assay were 2.5 (1a) and 5 pmol (1b). 
 
Fig. 5.  PAR binds to ASF/SF2 with higher affinity than to topo I. A): effect of high salt treatment on 
the stability of PAR-protein complexes. Recombinant proteins (5 pmol) were immobilized on 
nitrocellulose by slot blotting and either Gold stained (inset: a) or incubated with [32P]-PAR, followed 
by washes with either TBST or 0.5 M NaCl-TBST (inset: b and c, respectively). PAR-protein 
complexes were visualized by autoradiography (inset: b,c) and band intensities were quantified by 
scanning densitometry. Data are expressed as percent of controls (no salt treatment) and represent 
mean values ± SD of at least three independent experiments. 
B): competition binding functional assay. Topo I (0.2 pmol) was incubated with 5’-[32P]ds-
oligonucleotide substrate and ASF/SF2 in the absence or presence of increasing amounts of PAR. 
Topo I-DNA cleavage complexes were visualized by autoradiography following SDS-PAGE and 
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quantified by scanning densitometry. Data shown represent the mean ± SD of at least three 
independent experiments.  
 
Fig. 6. ASF/SF2-, but not histone phosphorylation by HeLa nuclear kinase(s) is inhibited by PAR. 
Protein phosphorylation assays were carried on in the absence or presence of increasing amounts of 
PAR, using 1 μg of HeLa nuclear protein and 7 pmol of either ASF/SF2 (A,B) or  histones, ie. H1 (9 
pmol) or H2B (14.5 pmol) (C). Lane 1 of the gel in A shows endogenous extract protein 
phosphorylation: no exogenous kinase substrate was added to the reaction mixture. In the experiment 
shown in B, ASF/SF2 phosphorylation was assayed in the presence of increasing amounts of CPT +/- 
plasmidic dsDNA. Phosphorylated proteins were visualized by autoradiography following incubation 
with [γ-32P]-ATP and separation by SDS-PAGE.  
 
Fig. 7. Regulation of topo I functions by PAR. The model illustrates PAR effects on distinct topo I 
activities and the likely mechanism underlying PAR-induced topo I functional switch.  
PAR interacts both with topo I and ASF/SF2 (double pointed arrows), with the latter forming more 
stable complexes (thicker double pointed arrow).  
In the absence of ASF/SF2, PAR targeting causes topo I to lose its DNA cleavage activity (A).  
ASF/SF2 is also a binding partner for topo I and a negative regulator of topo I catalyzed DNA 
cleavage; moreover, in the presence of ATP, ASF/SF2 reactivates a latent topo I kinase activity and 
becomes itself phosphorylated (B).  
When PAR, topo I and ASF/SF2 are present simultaneously, the two proteins compete for PAR 
binding: the formation of a PAR-ASF/SF2 high affinity complex leaves topo I free to direct its action 
on DNA (C).  In such a case, PAR acts as a modulator of the relative expression levels of topo I 
activities; in fact, whether topo I functions as a topoisomerase or as a kinase depends on PAR 
amounts: at low PAR concentrations, both DNA cleavage and protein phosphorylation can occur (C, 
left); DNA cleavage  activity is fully restored (at the detriment of the kinase activity) at higher PAR 
concentrations that titrate off ASF/SF2 from its interaction with topo I (C, right).  
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Table I – Incidence of alternative splicing among genes that are differentially expressed in cells or tissues lacking  
parp-1 and in their wild type counterparts, under physiological conditions or after cytotoxic stimuli 
------------------------------------------------------------------------------------------------------------------------------------------------------- 
     Cell type/tissue      treatment  differentially  alternatively       Data source 
               expressed genes       spliced genes (%)           (Ref.) 
parp-1 -/- versus wild type      
     Primary MEF  none      58          30 (51.7)  Simbulan-Rosenthal et al (51) 
     MES    none            291        164 (56.3)  Dechenes et al (52) 
     MES   none     86          46 (53.4)  Ogino et al (53) 
     Mouse liver  none     26          15 (57.6)  Ogino et al (53) 
 
Wild type treated versus wild type untreated 
     MHEC   TNF-α    43*          23 (53.5%)  Carrillo et al (54) 
 
parp-1 -/- treated versus parp-1 -/-  untreated 
     MHEC   TNF-α    39∗          23 (58.9%)  Carrillo et al (54) 
 
parp-1 -/- treated versus wild type treated 
     MHEC   TNF-α    18*          14 (72.2)  Carrillo et al (54) 
     Mouse heart  ischemia-reperfusion  31*          21 (67.7)  Zingarelli et al (55) 
------------------------------------------------------------------------------------------------------------------------------------------------------- 
 
MEF: mouse embryonic fibroblasts; MES: mouse embryonic stem cells; MHEC: mouse heart endothelial cells. 
*All these genes were similarly expressed in both parp-1 -/- and wild type untreated cells/tissues  
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